eCite Digital Repository
Malaria vaccines in the eradication era: current status and future perspectives
Wilson, KL and Flanagan, KL and Prakash, MD and Plebanski, M, Malaria vaccines in the eradication era: current status and future perspectives, Expert Review of Vaccines, 18, (2) pp. 133-151. ISSN 1476-0584 (2019) [Refereed Article]
Copyright 2019 Informa UK Limited, trading as Taylor & Francis Group
Introduction: The challenge to eradicate malaria is an enormous task that will not be achieved by current control measures, thus an efficacious and long-lasting malaria vaccine is required. The licensing of RTS, S/AS01 is a step forward in providing some protection, but a malaria vaccine that protects across multiple transmission seasons is still needed. To achieve this, inducing beneficial immune responses while minimising deleterious non-targeted effects will be essential.
Areas covered: This article discusses the current challenges and advances in malaria vaccine development and reviews recent human clinical trials for each stage of infection. Pubmed and ScienceDirect were searched, focusing on cell mediated immunity and how T cell subsets might be targeted in future vaccines using novel adjuvants and emerging vaccine technologies.
Expert commentary: Despite decades of research there is no highly effective licensed malaria vaccine. However, there is cause for optimism as new adjuvants and vaccine systems emerge, and our understanding of correlates of protection increases, especially regarding cellular immunity. The new field of heterologous (non-specific) effects of vaccines also highlights the broader consequences of immunization. Importantly, the WHO led Malaria Vaccine Technology Roadmap illustrates that there is a political will among the global health community to make it happen.
|Item Type:||Refereed Article|
|Keywords:||malaria vaccine, T cell, TBV, adjuvant, blood-stage, clinical trial, immune response; non-targeted effects, pre-erythrocytic|
|Research Division:||Biomedical and Clinical Sciences|
|Research Field:||Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)|
|Objective Group:||Clinical health|
|Objective Field:||Clinical health not elsewhere classified|
|UTAS Author:||Flanagan, KL (Dr Katie Flanagan)|
|Web of Science® Times Cited:||26|
Repository Staff Only: item control page